A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
- Mania
- Bipolar Disorder
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Bristol-Myers Squibb
- Enrolment target
- 424
- Started
- 8 October 2025
- Main results due (estimated)
- 28 June 2027
- Study ends (estimated)
- 28 June 2027
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Double (participant, investigator)
- Sites
- 109 · 5 in India
- First posted
- 26 August 2025
- Registry updated
- 3 November 2026
Can you take part?
- Ages 18 years to 65 years.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Individuals have a primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on the DSM-5-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI) version 7.0.2. * Individual is experiencing an acute exacerbation or relapse of manic episode, with or without mixed features (≤ 3 weeks). * The individual requires hospitalization for the acute exacerbation or relapse of mania. * Body mass index ≥ 18 and ≤ 40 kg/m2. * Currently experiencing an acute episode of mania or mania with mixed features with a therapeutic dose of lithium, valproate, or lamotrigine. The dose of the mood stabilizer must have remained stable for at least two weeks prior to screening. Additionally, participants on valproate must have been receiving treatment with valproate for a minimum of seven months. * YMRS Total Score of ≥ 18 at Screening and at Baseline, and \< 20% reduction in YMRS from screening to baseline. Exclusion Criteria: * Any primary DSM-5-TR disorder other than BP-I within 12 months before screening (confirmed using MINI version 7.0.2 at screening) including BP-I depression (for previous 3 months only), BP-I with rapid cycling, first manic episode, BP-II, primary psychotic disorder, borderline personality disorder, and major depressive disorder, with the exception of mild anxiety disorders. * Individual has a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before screening (confirmed using MINI version 7.0.2 at screening), or current use as determined by urine toxicology screen or alcohol test. * Risk for suicidal behavior at screening as determined by the investigator's clinical assessment and the C-SSRS with an answer "Yes" to item 4 or 5 within 6 months before screening or between screening and baseline, or "Yes" to any of the 5 items (C-SSRS behavior) with an event occurring within the 12 months before screening, or between screening and baseline. * History of irritable bowel syndrome (with or without constipation) or any serious constipation requiring treatment within the last 6 months. * History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma. * Participants with HIV, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or the LFT results. * Elevations in hepatic transaminases at screening ≥ 2 × ULN for ALT or AST and/or bilirubin \> 1.5× ULN, unless in the context of Gilbert's syndrome. * All grades of hepatic impairment (mild \[Child-Pugh Class A\], moderate \[Child-Pugh Class B\], and severe \[Child-Pugh Class C\]). * Other protocol-defined Inclusion/Exclusion criteria apply.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.
Keywords: Bipolar-I Disorder · Mania · KarXT · adjunctive treatment · mood stabilizer
What participants receive
- Experimental
KarXT + Lithium, Valproate, or Lamotrigine
Drug: Xanomeline/Trospium Chloride
- Placebo comparator
Placebo + Lithium, Valproate, or Lamotrigine
Drug: Placebo
Interventions
Xanomeline/Trospium ChlorideDrug
Also known as KarXT, BMS-986510
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
What the study measures
Primary outcomes
Change from baseline in Young Mania Rating Scale (YMRS) at Week 5
Time frame: At Week 5
Secondary outcomes
Change from baseline in Clinical Global Impressions Bipolar (CGI-BP) at Week 5
Time frame: At Week 5
Occurrence of response at Week 5 assessed as the number of participants with a ≥ 50% decrease from baseline in Young Mania Rating Scale (YMRS) score
Time frame: At Week 5
Occurrence of response at Week 5 assessed as the number of participants with a ≥ 1 change from baseline in CGI-BP
Time frame: At Week 5
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Week 7
Number of participants with Serious Adverse Events (SAEs)
Time frame: Up to Week 7
Number of participants with TEAEs leading to treatment discontinuation
Time frame: Up to Week 5
Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to Week 7
Change from baseline in Barnes Akathisia Rating Scale (BARS) at Week 5
Time frame: At Week 5
Change from baseline in Simpson Angus Scale (SAS) at Week 5
Time frame: At Week 5
Change from baseline in Abnormal Involuntary Movement Scale (AIMS) at Week 5
Time frame: At Week 5
Change from baseline in International Prostate Symptom Score (IPSS) at Week 5
Time frame: At Week 5
Who is running it
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Bristol-Myers Squibb
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- CN012-0046
- Other IDs
- 2025-521845-26, U1111-1321-1513, 2025
Bristol-Myers Squibb
Study director
Bristol-Myers Squibb
Study sites(109)
Local Institution - 0123
Madurai, Tamil Nadu, India
Not yet recruiting
Local Institution - 0118
Kolkata, West Bengal, India
Not yet recruiting
Local Institution - 0116
Kolkata, India
Not yet recruiting
Local Institution - 0207
Mangalore, India
Not yet recruiting
Local Institution - 0121
Mangaluru, Karnataka, India
Withdrawn
Pillar Clinical Research - Bentonville
Bentonville, Arkansas, United States
Recruiting
- Fayz Hudefi, Site 0029479-367-2688
Pillar Clinical Research- Little Rock
Little Rock, Arkansas, United States
Recruiting
- Leslie Smith, Site 0018501-350-3285
Clinical Innovations, Inc. dba CITrials
Bellflower, California, United States
Recruiting
- Gerald Maguire, Site 0110562-249-6956
Inland Psychiatric Medical Group.
Chino, California, United States
Recruiting
- Nandita Puchakayala, Site 0049909-488-9116
Proscience Research Group
Culver City, California, United States
Recruiting
- Marina Bussel, Site 0014424-227-8127
Omega Clinical Trials - La Habra
La Habra, California, United States
Recruiting
- Wakelin McNeel, Site 0151562-690-2200
Catalina Research Institute, LLC
Montclair, California, United States
Recruiting
- Stephen Volk, Site 0037909-590-8409
NRC Research Institute
Orange, California, United States
Recruiting
- Tony Ortiz, Site 0148714-289-1100
Clinical Innovations, Inc. dba CITrials
Riverside, California, United States
Recruiting
- Evagelos Coskinas, Site 0106951-300-4924
Health Synergy Clinical Research
Boynton Beach, Florida, United States
Recruiting
- Mohammad Nisar, Site 0016786-831-7303
CenExel iResearch, LLC
Savannah, Georgia, United States
Recruiting
- Yael Elfassy, Site 0136912-744-0800
Pillar Clinical Research -Chicago
Chicago, Illinois, United States
Recruiting
- Roueen Rafeyan, Site 0017312-865-6336
Arch Clinical Trials
St Louis, Missouri, United States
Recruiting
- Junaid Syed, Site 0023314-771-6387
Richmond Behavioral Associates
Staten Island, New York, United States
Recruiting
- Romana Kulikova, Site 0032718-619-4403
Community Clinical Research
Austin, Texas, United States
Recruiting
- David Brown, Site 0026512-323-2622
Adams Clinical Dallas
DeSoto, Texas, United States
Recruiting
Elevate Clinical Research-Houston
Houston, Texas, United States
Recruiting
Prime Clinical Research - Mansfield
Mansfield, Texas, United States
Recruiting
- Jamie Alexander, Site 0156817-907-7330
Pillar Clinical Research - Richardson
Richardson, Texas, United States
Recruiting
- Scott Bartley, Site 0033214-396-4844
Clinica El Jardin
Santiago del Estero, Argentina
Recruiting
- Gaston Noriega, Site 0114+5493854027710
State Psychiatric Hospital Sv. Ivan Rilski Novi Iskar
Novi Iskar, Bulgaria
Recruiting
- Tsveteslava Galabova, Site 0124359892444643
"University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD
Pleven, Bulgaria
Recruiting
- Maya Stoimenova - Popova, Site 0125+359888227165
Beijing Anding Hospital - Affiliated Capital University of Medical Science
Beijing, Beijing Municipality, China
Recruiting
- Qian Zhao, Site 018513811953687
Beijing HuiLongGuan Hospital
Beijing, Beijing Municipality, China
Recruiting
- Yunlong Tan, Site 0190010-83024302
Guangzhou Brain Hospital
Guangzhou, Guangdong, China
Recruiting
- Xuan Li, Site 019113902296157
Hebei Mental Health Center
Baoding, Hebei, China
Recruiting
- Yunshu Zhang, Site 019315533222271
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Recruiting
- Lehua Li, Site 019513787186559
Nanjing Brain Hospital
Nanjing, Jiangsu, China
Recruiting
Xi An Mental Health Center
Xi'an, Shaanxi, China
Recruiting
- Huali Lin, Site 018613679291619
The Fourth People's Hospital of Chengdu
Chengdu, Sichuan, China
Recruiting
- Feiyan Wang, Site 019213408419080
Tianjin Anding Hospital
Tianjin, Tianjin Municipality, China
Recruiting
- Lina Wang, Site 018813821577556
The Affilicated Kangning Hospital of Ningbo University
Ningbo, Zhejiang, China
Recruiting
- Yongming Xu, Site 019713655743461
Aalborg Universitetshospital Psykiatrien
Aalborg, North Denmark, Denmark
Recruiting
- René Nielsen, Site 005428722962
Glostrup Hospital
Glostrup Municipality, Denmark
Recruiting
- Bjørn Ebdrup, Site 0091+4538640840
Centre Hospitalier Universitaire de Clermont Ferrand
Clermont-Ferrand, France
Recruiting
- pierre michel Llorca, Site 00850473752124
Showing 40 of 109 sites. 75 recruiting, 25 not recruiting and 9 cancelled; 5 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
- What is shared
- Study protocol, Sap, Csr
- When
- See Plan Description
- Access
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Source: ClinicalTrials.gov record NCT07140913, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.